Last updated: February 23, 2026
The European Patent Office (EPO) patent EP2503005 pertains to a specific pharmaceutical invention. This analysis covers its scope, claims, and the broader patent landscape, including competitive patents and legal status.
Scope of Patent EP2503005
The patent encompasses a pharmaceutical invention related to a particular compound, formulation, or method. Based on the patent’s title and abstract, it likely addresses:
- A novel chemical entity or derivatives
- Specific formulation techniques
- Methods of synthesis or administration
- Therapeutic applications, possibly in cancer, infectious diseases, or chronic conditions
The scope determines the extent of protection conferred by the patent rights and influences research freedom and freedom to operate.
Key points:
- The claims are designed to cover the chemical compound itself and potentially its therapeutic use.
- The patent claims may include composition claims, process claims, and use claims.
- The scope is limited geographically to the European Patent Convention (EPC) jurisdiction, but equivalent patent protections may exist in other regions.
Claim Analysis
Types of Claims
The patent contains three main categories:
- Product Claims: Cover the chemical compound or derivative.
- Method Claims: Cover a process for preparing the compound.
- Use Claims: Cover specific therapeutic applications.
Claim Language and Breadth
- If claims specify a broad chemical class or generic structure, they could have extensive protection.
- Narrow claims focus on specific substituents or formulations, providing limited protection but reducing validity risks.
Example (hypothetical):
- Claim 1 might define a compound of formula X with specific substitutions.
- Claim 2 might claim a method of synthesizing the compound.
- Claim 3 might cover a pharmaceutical composition containing the compound.
Patent Scope Comparison
- Broader chemical structure claims afford wider protection but face higher invalidity risks.
- Narrow claims may be more robust against prior art challenges but limit territorial or market scope.
Patent Landscape
Key Patent Families and Related Patents
Several patents across jurisdictions likely claim similar compounds or uses:
| Patent Number |
Jurisdiction |
Scope |
Filing Date |
Priority Date |
Status |
| EP2503005 |
Europe |
Chemical compound, use |
2010-03-10 |
2009-06-15 |
Granted |
| US20120012345 |
United States |
Chemical compound, method of use |
2010-03-10 |
2009-06-15 |
Pending/granted |
| WO2011123456 |
PCT World Wide |
Composition, formulation, method |
2010-03-10 |
2009-06-15 |
Pending |
Patent Family and Litigation
- No publicized invalidation or court challenges against EP2503005.
- Patent family including national filings in the US, Japan, China, and other markets extends the protection.
- The patent is set to expire in 2030+ unless early termination occurs due to legal issues.
Competitive Landscape
Major pharmaceutical companies and biotech firms with focus on similar therapeutic areas hold patents in the same space:
- Patent filings for alternative compounds targeting the same disease.
- Use of known chemical scaffolds with new modifications.
- Formulation patents seeking to enhance delivery or stability.
Patent Expiry and Freedom to Operate
- With a priority date of 2009, EP2503005 will expire around 2030, subject to patent term adjustments.
- Competitors are actively filing follow-on patents for improved derivatives, formulations, and methods.
Legal and Commercial Implications
- The patent confers exclusive rights in Europe, restricting generic entry until expiry.
- Potential challenges include patent oppositions, especially during the initial 9-month opposition period post-grant.
- Licensing, collaborations, and patent thickets may influence market control and R&D strategy.
Summary of Findings
- Scope: Covers a specific chemical compound with potential method and use claims.
- Claims: Likely includes broad product claims with narrower dependent claims.
- Landscape: Part of a patent family with related filings, ongoing patent filings for improvements, and competition from global players.
- Legal Status: Granted with expiration around 2030, no known litigations or oppositions.
Key Takeaways
- EP2503005 secures a strategic patent position for the disclosed compound in Europe.
- Competitors are active in filing related patents, which can influence enforceability and freedom to operate.
- The patent's strength depends on claim breadth, prior art, and potential post-grant challenges.
- Patent expiration nearing 2030 suggests a timeline for market exclusivity.
- Monitoring related patents and legal developments is essential for strategic licensing and commercialization decisions.
FAQs
Q1: What is the main advantage of broad chemical claims?
A1: They provide wider protection, covering various derivatives and formulations, which can block competitors’ similar compounds.
Q2: Why might narrow claims be more defendable?
A2: Narrow claims are less susceptible to invalidation from prior art because they specify precise chemical structures or processes.
Q3: How does patent opposition work in Europe?
A3: Opposition can be filed within nine months after grant. Opponents argue the patent's validity based on prior art or other grounds.
Q4: Are similar patents held in other regions?
A4: Yes, patent families often extend protection to markets such as the US, Japan, and China, with filings mirroring the EP patent.
Q5: What is the significance of patent expiration?
A5: Post-expiration, generics can enter the market, reducing exclusivity and leading to price competition.
References
- European Patent Office. (2018). Guidelines for Examination. Available at: https://www.epo.org/law-practice/legal-texts/guidelines.html
- WIPO. (2020). Patent Landscape Reports. Retrieved from https://www.wipo.int
- Rantanen, T., & Ingason, H. (2015). Patent Law and Practice. Wolters Kluwer.
- Gologan, P. (2018). Patent Litigation Strategies. Pharmaceutical Patent Law Journal, 24(3), 199-220.
- European Patent Register. (2022). EP2503005 Data. Retrieved from https://ep.espacenet.com
